TREATMENT OF ACROMEGALY BY TRANS-SPHENOIDAL OPERATION, 90-YTTRIUM IMPLANTATION AND BROMOCRIPTINE: RESULTS IN 230 PATIENTS

Publisher Website
Google Scholar
Abstract
Two hundred and thirty patients with acromegaly were diagnosed and treated in a prospective cooperative study in twelve university clinics. Primary treatment was: trans-sphenoidal surgery (152 patients), trans-sphenoidal surgery with additional cryotherapy (18 patients), Yttrium-90-implantation (30 patients), bromocriptine (30 patients). The results of endocrine assessment before treatment and 6 mo. after operation, 90-Y implantation or commencement of bromocriptine therapy are reported. The best results (low GH [growth hormone], no or little deterioration of pituitary function, low complication rate) were achieved by trans-sphenoidal surgery, especially in patients with intrasellar tumors (basal GH < 5 ng/ml in 59.7%). Results were less good with increasing tumor size. Additional cryosurgery was accompanied by a high rate of anterior pituitary insufficiency and is no longer employed. Y-90-implantation resulted in less improvement in GH levels (basal GH < 5 ng/ml in 51.7% of patients with intrasellar tumors), a high rate of pituitary insufficiency and more complications. Bromocriptine treatment was least effective in lowering GH concentrations (basal GH < 5 ng/ml in 33% of patients with intrasellar tumors). Different criteria for treatment success were compared. In the entire group, basal GH concentrations below 5 ng/ml were attained in 51.7% of all patients whose values were higher than this prior to treatment. Suppressibility of GH below 2 ng/ml during glucose loading occurred in only 34.9%. An abnormal GH response to TRH/LHRH was present in 47.2% before and in 43.4% after/during treatment. The prognostic significance of this latter finding must be evaluated by further study.